Edgewise Therapeutics (EWTX)
(Real Time Quote from BATS)
$35.19 USD
-0.32 (-0.90%)
Updated Oct 18, 2024 01:54 PM ET
3-Hold of 5 3
C Value F Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Edgewise Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 318 | 352 | 281 | 129 | -99,999 |
Receivables | 0 | 0 | 0 | 0 | NA |
Notes Receivable | 0 | 0 | 0 | 0 | NA |
Inventories | 0 | 0 | 0 | 0 | NA |
Other Current Assets | 9 | 5 | 3 | 1 | NA |
Total Current Assets | 327 | 357 | 284 | 130 | NA |
Net Property & Equipment | 10 | 9 | 1 | 1 | NA |
Investments & Advances | 0 | 0 | 0 | 0 | NA |
Other Non-Current Assets | 0 | 0 | 0 | 0 | NA |
Deferred Charges | 0 | 0 | 0 | 0 | NA |
Intangibles | 0 | 0 | 0 | 0 | NA |
Deposits & Other Assets | 0 | 0 | 1 | 1 | NA |
Total Assets | 340 | 367 | 285 | 131 | NA |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | NA |
Accounts Payable | 4 | 6 | 4 | 2 | NA |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | NA |
Accrued Expenses | 12 | 10 | 7 | 3 | NA |
Income Taxes Payable | 0 | 0 | 0 | 0 | NA |
Other Current Liabilities | 0 | 0 | 0 | 0 | NA |
Total Current Liabilities | 17 | 17 | 11 | 4 | NA |
Mortgages | 0 | 0 | 0 | 0 | NA |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | NA |
Convertible Debt | 0 | 0 | 0 | 0 | NA |
Long-Term Debt | 0 | 0 | 0 | 0 | NA |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | NA |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | NA |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | NA |
Total Liabilities | 21 | 20 | 11 | 4 | NA |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 160 | NA |
Common Stock (Par) | 0 | 0 | 0 | 0 | NA |
Capital Surplus | 563 | 493 | 352 | 1 | NA |
Retained Earnings | -245 | -145 | -77 | -34 | NA |
Other Equity | 0 | -1 | -1 | 0 | NA |
Treasury Stock | 0 | 0 | 0 | 0 | NA |
Total Shareholder's Equity | 319 | 347 | 274 | 127 | NA |
Total Liabilities & Shareholder's Equity | 340 | 367 | 285 | 131 | NA |
Total Common Equity | 319 | 347 | 274 | -33 | 0 |
Shares Outstanding | 70.40 | 63.20 | 49.30 | NA | NA |
Book Value Per Share | 4.53 | 5.49 | 5.57 | 0.00 | 0.00 |
Fiscal Year End for Edgewise Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 512 | 533 | 318 | 290 |
Receivables | NA | 0 | 0 | 0 | 0 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 0 | 0 | 0 | 0 |
Other Current Assets | NA | 8 | 9 | 9 | 8 |
Total Current Assets | NA | 519 | 541 | 327 | 298 |
Net Property & Equipment | NA | 10 | 10 | 10 | 11 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 532 | 554 | 340 | 311 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 7 | 5 | 4 | 5 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 9 | 9 | 12 | 10 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 17 | 15 | 17 | 16 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 21 | 19 | 21 | 21 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 816 | 809 | 563 | 505 |
Retained Earnings | NA | -305 | -273 | -245 | -215 |
Other Equity | NA | -1 | -1 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 510 | 535 | 319 | 290 |
Total Liabilities & Shareholder's Equity | NA | 532 | 554 | 340 | 311 |
Total Common Equity | 0 | 510 | 535 | 319 | 290 |
Shares Outstanding | 93.70 | 93.40 | 93.10 | 70.40 | 63.40 |
Book Value Per Share | 0.00 | 5.47 | 5.75 | 4.53 | 4.58 |